University of Toronto
Toronto, Ontario, M5S2C9, Canada
Location status: Recruiting
NCT Number: NCT06776458
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. Despite the evidence that aromatase inhibitor therapy is associated with increased risk of cardiovascular events, potentially related to the duration of use, no studies have been conducted to characterize the long-term effects of aromatase inhibitor therapy on the heart or vessel structure and function as underlying determinants of cardiovascular mortality. This study will characterize the long-term effects of aromatase inhibitor therapy on established and novel health indices for CVD in breast cancer patients, by examining cross-sectionally compare health indices 1-, 5- and 10-years post-diagnosis in breast cancer survivors to controls. Specifically, our objectives are as follows:
1. To examine the effects of aromatase inhibitor therapy on early risk indicators for cardiovascular disease in the peripheral vasculature and heart, including aortic stiffness (primary outcome) and secondary outcomes of peripheral and carotid artery stiffness, blood biomarkers (lipids), blood pressure, carotid intima media thickness, endothelial function, and left ventricular ejection fraction, global longitudinal strain, and left ventricular diastolic function, in breast cancer survivors compared to controls. 2. To examine the effects of aromatase inhibitor therapy on factors related to cerebrovascular health, autonomic regulation, and cognitive function, including BDNF, heart rate variability, cerebrovascular function in response to a supine-sit-stand maneuver and squatting challenge, and a core battery of cognitive function tests, in breast cancer survivors compared to controls. 3. To examine the effects of aromatase inhibitor therapy on body composition, bone mineral density, and protein metabolism, in breast cancer survivors compared to controls. 4. To examine the effects of aromatase inhibitor therapy on lifestyle factors (behavioural), including diet, physical activity (including cardiorespiratory fitness), sleep, stress, and quality of life, in breast cancer survivors compared to controls.
The investigators hypothesize that biologic and behavioural cardiovascular health indices will be deteriorated relative to controls as early as 1 year post-diagnosis and that prolonged use will further accelerate aging-related impairments.
Interested in participating?
Request InfoFemale
Observational
Toronto, Ontario, M5S2C9, Canada
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Case group:
Control group:
Exclusion criteria
Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.
Time frame: Day 2 (In-Person Session)
Aortic stiffness, measured non-invasively by pulse wave velocity, will be assessed using applanation tonometry.
Time frame: Day 2 (In-Person Session)
Endothelial function will be assessed using the gold standard method of flow mediated dilation (FMD) using non-invasive duplex ultrasound (GE Vivid IQ) and edge-tracking software.
Time frame: Day 2 (In-Person Session)
Functional assessment of the carotid artery stiffness will be assessed using B-mode ultrasound and artery edge-tracking software
Time frame: Day 2 (In-Person Session)
Structural assessment of the carotid artery thickness will be assessed using B-mode ultrasound and artery edge-tracking software
Time frame: Day 2 (In-Person Session)
Measured by Pulse Wave Velocity (PWV) of the arm and leg
Time frame: Day 2 (In-Person Session)
Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, represented as a % using the following formula: stroke volume/end diastolic volume x 100%.
Time frame: Day 2 (In-Person Session)
Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, expressed as a percentage of the relative change in length of the left ventricle through a cardiac cycle.
Time frame: Day 2 (In-Person Session)
Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, assessed by the ratio of peak early diastolic velocity to peak mitral valve velocity (E/A ratio).
Time frame: Day 2 (In-Person Session)
Cerebral blood flow velocity response (delta change compared to rest) of the middle cerebral artery will be assessed using transcranial Doppler ultrasound (Neurovision Transcranial Doppler System Model 500M) in accordance with recent guidelines, in response to postural changes (sit-to-stand) and exercise (squatting).
Time frame: Day 2 (In-Person Session)
Brain derived neurotrophic factor will be assessed via fasted venipuncture using in-house assays.
Time frame: Day 2 (In-Person Session)
HDL, LDL, total Cholesterol, Triglycerides analyzed from blood serum using a clinical assay at a core lab.
Time frame: Day 2 (In-Person Session)
Analyzed from blood plasma using a clinical assay at a core lab.
Time frame: Day 2 (In-Person Session)
Calculated as Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) from fasting blood measures of glucose and insulin, analyzed using a clinical assay at a core lab.
Time frame: Day 1 (At-Home Session)
Analyzed from breathing test and urine sample before and after the participant consume a test protein drink.
Time frame: Day 2 (In-Person Session)
Measured as peak volume of oxygen consumption via indirect calorimetry during a cardiopulmonary exercise test on a cycle ergometer.
Time frame: Day 2 (In-Person Session)
Calculated using the standardized scoring system where sex-specific points are assigned to age, systolic blood pressure (dependent on treatment status), HDL, total cholesterol, smoking and diabetes status. The range for females is 0-30% where a higher score indicates a greater risk of cardiovascular disease in the next 10 years.
Time frame: Day 2 (In-Person Session)
Measured as the difference between peak heart rate during the cardiorespiratory fitness test and heart rate 2-minutes into active recovery after stopping the exercise test.
Time frame: Day 2 (In-Person Session)
Measured as the variability in beat-to-beat heart rate during supine rest.
Time frame: Day 2 (In-Person Session)
Measured by a non-invasive optical technique used to assess tissue oxygenation and hemodynamics (Near-Infrared Spectroscopy - NIRS) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.
Time frame: Day 2 (In-Person Session)
Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.
Time frame: Day 2 (In-Person Session)
Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.
Time frame: Day 2 (In-Person Session)
Measured as the average of the last 5 of 6 blood pressure measurements taken 60 seconds apart using an automatic blood pressure device.
Time frame: Day 2 (In-Person Session)
Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.
Time frame: Day 2 (In-Person Session)
Analyzed from blood plasma using a clinical assay at a core lab.
Time frame: Day 2 (In-Person Session)
Measured using a body composition device (BodPod) to estimate whole body fat (in kg and %) and fat free mass (in kg and %).
Time frame: Day 2 (In-Person Session)
Circumferences of the waist, hip and neck, measured using an inelastic tape
Time frame: Day 2 (In-Person Session)
Assessed using a dual x-ray absorptiometry scan.
Time frame: Day 2 (In-Person Session)
Assessed fasted in lab using a calibrated scale
Time frame: Day 2 (In-Person Session)
Calculated from a measurement of height using a stadiometer and body weight (detailed above).
Time frame: Day 1 (At-Home Session)
Various components of dietary intake including macronutrients and micronutrients will be assessed through 3-day food records over 2 weekdays and 1 weekend collected using ASA-24 online system.
Time frame: Day 1 (At-Home Session)
An overall measure of alignment with Canada's dietary guidelines measured via the Healthy Eating Food Index-2019 calculated from 3-day diet records
Time frame: Day 1 (At-Home Session)
Measured by the Hospital Anxiety and Depression Scale (HADS); score ranges from 0-21 for each of depression and anxiety with a higher score indicating more severe depression or anxiety
Time frame: Day 1 (At-Home Session)
Assessed by the COMPASS 31 (Composite Autonomic Symptom Score) questionnaire. This questionnaire provides clinically relevant scores of autonomic symptom severity. Scores range from 0 to 31 with questions in six domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor, with a higher scoring indicating worse autonomic dysfunction.
Time frame: Day 2 (In-Person Session)
Assessed using the Controlled Oral Word Association of the Multilingual Aphasia Exam (verbal fluency), with higher number of words produced indicative of better cognitive health.
Time frame: Day 2 (In-Person Session)
Assessed the Hopkins Verbal Learning Test (learning, memory) with an immediate recall, delayed recall, and recognition accuracy from a list of 12 words. Higher number of words are indicative of better cognitive health.
Time frame: Day 2 (In-Person Session)
Assessed by the Trail Making Test (attention, speed, executive function). Shorter test time on 2 forms of the test is indicative of better cognitive health.
Time frame: Day 2 (In-Person Session)
Assessed by Global Deficit Score (GDS). GDS is calculated as an average score from 3 tests: 1) Hopkins Verbal Learning Test (learning, memory), 2) Trail Making Test (attention, speed, executive function), 3) Controlled Oral Word Association of the Multilingual Aphasia Exam (verbal fluency). Each subtest of the GDS has a complex scoring system, detailed above, with higher values indicating greater cognitive deficits.
Time frame: Day 1 (At-Home Session)
Assessed using the Functional Assessment of Cancer Therapy - General (FACT-G), - Endocrine (FACT-ES), Cognitive (FACT-Cog) and - Fatigue (FACT-F). These are patient-reported outcome measurements used to assess health-related quality of life in patients with a history of cancer. The FACT-G is calculated from the sum of four subscales on general health related quality of life with a range of 0-108 points. The FACT-ES is a score of 19 questions with scores ranging from 0-76. The FACT-Cog contains 37 questions with a score of 0 to 132. FACT-F is calculated from the sum of 13 questions. Higher scores on each scale is indicative of better quality of life.
Time frame: Day 1 (At-Home Session)
Assessed using the Musculoskeletal Health Questionnaire (MSK-HQ). The MSK-HQ is a series of 15 questions with a range from 0-56 with higher scores being indicative of poorer MSK health.
Time frame: Day 1 (At-Home Session)
Assessed using the Brief Pain Inventory (BPI). The BPI is scored as the average of seven pain-related questions with a range of 0-10 with higher scores representing greater pain.
Time frame: Day 1 (At-Home Session)
Assessed using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index. The WOMAC is a series of 17 questions resulting in a % (0-100) with higher scores indicative of greater osteoarthritis index.
Time frame: Day 1 (At-Home Session)
Assessed using the Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire. The DASH contains 30 questions with scores of 0 to 100 with higher scores representing higher severity in disability.
Time frame: Day 1 (At-Home Session)
Assessed using the INTERHEART Risk Score, a validated score for quantifying risk-factor burden without the use of laboratory testing (with higher scores indicating greater risk-factor burden).
Time frame: Day 1 (At-Home Session)
Assessed by the Stanford Gender-related Variables for Health Research (GVHR) which includes questions related to seven gender-related variables: caregiver strain, work strain, independence, risk-taking, emotional intelligence, social support, and discrimination.
Time frame: Day 1 (At-Home Session)
Assessed by RAND-36, where an independent score is provided for 8 scales ranging from 0 to 100 and 2 component summary scales ranging from 0-50 with a higher score indicating better quality of life.
Time frame: Day 1 (At-Home Session)
Assessed by the perceived stress scale (PSS-14) where individual scores can range from 0 to 56 with higher scores indicating higher perceived stress
Time frame: Day 1 (At-Home Session)
Subjectively assessed by the Pittsburgh Sleep Quality Index (PQSI), which measures components of sleep: sleep duration, disturbance, sleep latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep quality, and sleep medication use, with higher scores reflecting poorer sleep quality. From these 7 questions, a global score of 0 to 21 is created with higher values indicative of poorer sleep quality.
Time frame: Day 1 (At-Home Session)
Measured via Garmin smartwatch for the total sleep duration and efficiency.
Time frame: Day 1 (At-Home Session)
Measured via Garmin smartwatch for time in moderate-vigorous physical activity, and step counts.
Time frame: Day 1 (At-Home Session)
Measured via Garmin smartwatch for time spent sitting.
Contact information is provided by the study sponsor or research team.
University of Toronto
Other
Beyond Cardiotoxicity: Characterizing the Long-term Cardiovascular Side Effects of Breast Cancer Endocrine Treatment
Acronym: STRIVE-Chronic
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07213271
Breast Cancer Females
Bratislava, Slovakia
View Trial DetailsNCT07657130
Breast Cancer Females, Breast Diseases
Shenyang, Liaoning, China
View Trial DetailsNCT07097155
Breast Cancer Females, Breast Diseases
Reus, Tarragona, Spain
View Trial DetailsNCT07378319
Breast Cancer Females, Breast Diseases
Taichung, Taiwan
View Trial Details